The development of IL-6R superantagonists should allow the role of IL-6 in hormone-dependent and -independent conditions, such as breast and prostate cancer, to be elucidated and may lead to their use as novel therapeutic options for their treatment. The gene discussed is IL6R; the disease is Familial prostate cancer.